title: Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE.
authors: University Hospital Aintree, Department of Diabetes & Endocrinology, Clinical Sciences Centre, Liverpool L9 7AL, United Kingdom. rebecca.dobson@liverpool.ac.uk
authors: Rebecca
authors: R
authors: Dobson
authors: Sobhan
authors: S
authors: Vinjamuri
authors: James
authors: J
authors: Hsuan
authors: Melissa
authors: M
authors: Banks
authors: Monica
authors: M
authors: Terlizzo
authors: Hulya
authors: H
authors: Wieshmann
authors: Christina
authors: C
authors: Daousi
authors: Graeme P
authors: GP
authors: Poston
authors: Daniel J
authors: DJ
authors: Cuthbertson
mesh_terms: D000368:Aged; D006801:Humans; D008187:Lutetium / Q000008:administration & dosage*; D008297:Male; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009918:Orbital Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D009942:Organometallic Compounds / Q000008:administration & dosage*; D011868:Radioisotopes / Q000008:administration & dosage*; D019275:Radiopharmaceuticals / Q000008:administration & dosage*
chemical_list: D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D008187:Lutetium; C447941:lutetium Lu 177 dotatate; D015282:Octreotide